Role of Radioimmunoassay in the Cardiac Patient—Principles and Applications
The English physician William Withering introduced digitalis therapy for the management of cardiac disorders around 200 years ago. Although the crude preparations were effective in heart failure, they were accompanied by gastrointestinal upset, visual disturbances, and often death. The dangers associated with digitalis therapy have continued to plague physicians until the present day, since they have had to contend with the narrow margin that exists between beneficial dosage and dosage resulting in toxicity, the variations in tolerance, absorption, excretion, sensitivity, and the lack of a sensitive assay for monitoring the drug blood and tissue levels.
KeywordsNuclear Cardiology Cardiac Disorder Digoxin Level Digoxin Toxicity Crude Preparation
Unable to display preview. Download preview PDF.
- 1.Ashkar, F. S., Practical Nuclear Medicine, Medcom Press, New York (1974).Google Scholar
- 2.Butler, V. P. Jr., Digoxin: Immunologic approaches to measurement and reversal of toxicity, N. Engl. J. Med. 383:1150 (1970).Google Scholar
- 4.Duhme, D. W., Greenblatt, D. J., and Koch-Weser, J., Reduction of digoxin toxicity associated with measurement of serum levels, Ann. Intern. Med. 80:516 (1974).Google Scholar
- 5.Smith, T. W., Butler, V. P. Jr., and Harber, E., Determination of therapeutic and toxic serum digoxin concentration by radioimmunoassay, N. Engl. J. Med. 281:1212 (1969).Google Scholar